Efficacy and safety considerations for IPSC-derived cell therapies
15 Apr 2025
Cell Therapy Development
- What preclinical characteristics are most convincing that an IPSC-derived cell therapy will be optimally efficacious in the clinic?
- What approaches are being employed for clinical safety regarding tumorigenicity, immunogenicity and genetic instability in IPSC-derived cell therapies?
- Compared with autologous cell therapies or other therapeutic modalities, what advantages/disadvantages do IPSC-derived cell therapies possess?
- Where do you see the next-generation IPSC-derived cell therapies going to enhance efficacy and safety of the current generation?
